Morgan Stanley upgrades AstraZeneca to Overweight

  • Investing.com
Morgan Stanley upgrades AstraZeneca to Overweight
Credit: © Reuters.

A Morgan Stanley analyst upgraded AstraZeneca (LON: AZN) from Equalweight to Overweight with a price target of $132.00 from a prior price target of %currency%%price%.

Prior to this rating, AstraZeneca had 23 buy ratings, 7 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on AstraZeneca, click here. For more news on AstraZeneca, click here.

AstraZeneca's stock price closed at $11.0. They are up -99.9% in the last month and up 11.2% in the last 12 months.

According to Investing Pro, AstraZeneca's fair value is $130.2, an upside of 11.2%. AstraZeneca's fair value comes with a low degree of uncertainty, according to InvestingPro.

Check out AstraZeneca's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles